Shares of other companies:
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
DXCM Stock News and Mentions of DexCom, Inc. Stocktwits
Updated: April 28, 2024 (09:14)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where DexCom Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of DexCom, Inc. (DXCM).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the DexCom stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of DexCom, Inc. (DXCM)
April 26, 2024 (17:54) / "Investors Business Daily" (by KIMBERLEY KOENIG)
Google Helps Lift Nasdaq, Microsoft And Amazon Lead Dow Jones
Stock Market Today: Google Lifts Nasdaq As Amazon, Microsoft Lead Dow Jones Investor's Business Daily ...
In Article Trend: Neutral
April 26, 2024 (15:34) / "Investors Business Daily" (by Investor's Business Daily)
Stocks Rebound Amid Big-Cap Earnings: Weekly Review
Stock Market Rebounds. Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review Investor's Business Daily ...
In Article Trend: Neutral
April 26, 2024 (14:43) / "Investors Business Daily" (by Investor's Business Daily)
Surging Alphabet Stock Leads Broad-Based Tech Rally As Market Stages Recovery
Stocks were off to a strong start Friday after a resilient performance Thursday that saw the Nasdaq composite pare a 2.3% intraday loss to less than 1%. Microsoft ( MSFT ) and Google-parent Alphabet ( GOOGL ) were strong movers on the stock market today, but the Dow Jones Industrial Average could ...
In Article Trend: Somewhat-Bullish
April 26, 2024 (12:20) / "Investors Business Daily" (by SCOTT LEHTONEN)
Tech Futures Lead Ahead Of Inflation Data
Stock Market Today: Dow Jones Rises Ahead Of Inflation Data. Google, Microsoft Surge Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 26, 2024 (12:18) / "Benzinga" (by Avi Kapoor)
Why Alphabet Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Alphabet ( NASDAQ:GOOGL )
Shares of Alphabet Inc. GOOGL GOOG rose sharply in today's pre-market trading the company posted upbeat results for its first quarter. Google parent Alphabet said its first-quarter revenue increased 15% year-over-year to $80.539 billion, beating the consensus estimate of $78.594 billion.
In Article Trend: Somewhat-Bullish
April 26, 2024 (11:29) / "Zacks Commentary" (by Zacks Equity Research)
DexCom ( DXCM ) Q1 Earnings Beat, Strong CGM Demand Continues
DexCom's (DXCM) first-quarter 2024 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
In Article Trend: Somewhat-Bullish
April 26, 2024 (10:26) / "Benzinga" (by Avi Kapoor)
Intel Reports Weak Sales, Joins Boyd Gaming, Atlassian And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Intel ( NASDAQ:INTC ) , Atlassian ( NASDAQ:TEAM ) , Boyd Gaming ( NYSE:BYD )
U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 150 points on Friday. Shares of Intel Corporation INTC shares fell sharply in today's pre-market trading after the company reported worse-than-expected first-quarter sales results and issued EPS guidance below ...
In Article Trend: Neutral
April 26, 2024 (07:00) / "Investors Business Daily" (by Investor's Business Daily)
Edwards Lifesciences Clears Technical Benchmark, Hitting 80-Plus RS Rating
When considering what names to put on your watch list, focus on stocks with an 80 or higher RS Rating. Edwards Lifesciences ( EW ) just cleared that benchmark with an upgrade from 77 to 82. X IBD's unique rating measures price movement with a 1 ( worst ) to 99 ( best ) score.
In Article Trend: Somewhat-Bullish
April 26, 2024 (07:00) / "Investors Business Daily" (by Investor's Business Daily)
Align Technology Hits 80-Plus Relative Strength Rating Benchmark
On Friday, Align Technology ( ALGN ) hit an important technical milestone, with its Relative Strength ( RS ) Rating moving into the 80-plus percentile with an upgrade to 81, up from 68 the day before. X This exclusive rating from Investor's Business Daily identifies market leadership with a 1 ...
In Article Trend: Somewhat-Bullish
April 26, 2024 (05:30) / "Motley Fool" (by Motley Fool Transcribing)
DexCom ( DXCM ) Q1 2024 Earnings Call Transcript
DXCM earnings call for the period ending March 31, 2024.
In Article Trend: Somewhat-Bullish
April 25, 2024 (20:40) / "Investors Business Daily" (by ED CARSON)
Tech Futures Jump On Google, Microsoft
Dow Jones Futures Rise. Microsoft Pops, Google Soars After Stock Market Rally Shows Resilience Investor's Business Daily ...
In Article Trend: Neutral
April 25, 2024 (20:15) / "Benzinga" (by Benzinga Insights)
Peering Into DexCom's Recent Short Interest - DexCom ( NASDAQ:DXCM )
DexCom's DXCM short percent of float has fallen 8.15% since its last report. The company recently reported that it has 14.57 million shares sold short, which is 4.28% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.06 days to cover their ...
In Article Trend: Somewhat-Bullish
April 25, 2024 (20:12) / "Investors Business Daily" (by Investor's Business Daily)
Diabetes Devices Giant Crumbles Despite Beat-And-Raise
Dexcom Stock Crumbled After Beating First-Quarter Views, Raising Sales Guide Investor's Business Daily ...
In Article Trend: Neutral
April 25, 2024 (19:43) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Staar Surgical Stock Climbs The Leadership Ladder With Jump To 84 RS Rating
Staar Surgical ( STAA ) stock had its Relative Strength ( RS ) Rating upgraded from 80 to 84 Thursday. This unique rating identifies technical performance by using a 1 ( worst ) to 99 ( best ) score that identifies how a stock's price action over the last 52 weeks matches up against other ...
In Article Trend: Somewhat-Bullish
April 25, 2024 (12:30) / "Investors Business Daily" (by ALLISON GATLIN)
How Big Pharma Is Taking A Page Out Of Novartis' Playbook
Biotech Stocks: Big Pharma Eyes $25 Billion Radiopharmaceuticals Market Investor's Business Daily ...
In Article Trend: Neutral
April 25, 2024 (12:07) / "Investors Business Daily" (by Investor's Business Daily)
Futures Slide On Meta Stock Plunge
Stock Market Today: Dow Jones Slides On Meta Stock Plunge. Google, Microsoft Earnings Next Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 25, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
DexCom Shows Rising Price Performance With Jump To 83 RS Rating
On Thursday, DexCom ( DXCM ) received a positive adjustment to its Relative Strength ( RS ) Rating, from 79 to 83. X IBD's unique RS Rating identifies technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
In Article Trend: Somewhat-Bullish
April 25, 2024 (07:00) / "Investors Business Daily" (by Investor's Business Daily)
Staar Surgical Shows Market Leadership With Jump To 84 RS Rating
Staar Surgical ( STAA ) had its Relative Strength ( RS ) Rating upgraded from 80 to 84 Thursday. X This unique rating identifies technical performance by using a 1 ( worst ) to 99 ( best ) score that identifies how a stock's price action over the last 52 weeks matches up against other ...
In Article Trend: Somewhat-Bullish
April 24, 2024 (13:30) / "Zacks Commentary" (by Zacks Equity Research)
Wall Street Bulls Look Optimistic About DexCom ( DXCM ) : Should You Buy?
Based on the average brokerage recommendation (ABR), DexCom (DXCM) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
In Article Trend: Somewhat-Bullish
April 24, 2024 (12:07) / "Investors Business Daily" (by SCOTT LEHTONEN)
Futures Rise As Tesla Soars On Earnings
Stock Market Today: Dow Jones Rises As Boeing, Tesla Jump On Earnings. Meta Earnings Next Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 24, 2024 (08:18) / "Stocknews.com" (by Defense World Staff)
DexCom ( NASDAQ:DXCM ) Rating Lowered to Hold at StockNews.com
StockNews.com downgraded shares of DexCom ( NASDAQ:DXCM - Free Report ) from a buy rating to a hold rating in a research report released on Tuesday. Other research analysts have also recently issued reports about the company. Royal Bank of Canada began coverage on DexCom in a research report on ...
In Article Trend: Somewhat-Bullish
April 24, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Stocks To Watch: Tandem Diabetes Care Sees Relative Strength Rating Rise To 92
Tandem Diabetes Care ( TNDM ) had its Relative Strength ( RS ) Rating upgraded from 86 to 92 Wednesday. X IBD's proprietary rating tracks share price performance with a 1 ( worst ) to 99 ( best ) score. The rating shows how a stock's price behavior over the last 52 weeks compares to all the ...
In Article Trend: Bullish
April 24, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Establishment Labs Hldgs Shows Improved Relative Strength; Still Shy Of Benchmark
Establishment Labs Hldgs Shows Improved Relative Strength. Still Shy Of Benchmark Investor's Business Daily ...
In Article Trend: Bullish
April 23, 2024 (13:29) / "Zacks Commentary" (by Zacks Equity Research)
DexCom ( DXCM ) to Report Q1 Earnings: What's in the Cards?
DexCom's (DXCM) first-quarter 2024 results are likely to reflect rising volumes across all channels.
In Article Trend: Somewhat-Bullish
April 23, 2024 (12:19) / "Investors Business Daily" (by Investor's Business Daily)
Futures Extend Gains As GM Jumps On Earnings
Stock Market Today: Dow Jones Rises As GM Surges On Earnings Beat. Tesla Earnings Next Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 22, 2024 (21:13) / "Investors Business Daily" (by SCOTT LEHTONEN)
Futures: Big Earnings Reports This Week
Dow Jones Futures: Nvidia Stock Rebounds. Google, Microsoft, Meta, Tesla Set To Report Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 22, 2024 (13:16) / "Zacks Commentary" (by Zacks Equity Research)
Ahead of DexCom ( DXCM ) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for DexCom (DXCM), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
In Article Trend: Somewhat-Bullish
April 22, 2024 (13:01) / "Zacks Commentary" (by Zacks Equity Research)
Zacks Investment Ideas feature highlights: Vertiv, Align Technology and DexCom
Vertiv, Align Technology and DexCom are part of the Zacks Investment Ideas article.
In Article Trend: Neutral
April 21, 2024 (14:24) / "Investors Business Daily" (by ED CARSON)
Futures Due After AI Meltdown; Tesla Cuts Prices With Earnings Due
Dow Jones Futures Loom After Nvidia, Super Micro Plunge. Tesla Slashes Prices With Earnings Due Investor's Business Daily ...
In Article Trend: Neutral
April 19, 2024 (20:43) / "Investors Business Daily" (by ED CARSON)
Market Reels As Nvidia, SMCI Crack; Here's What To Do Now
Dow Jones Futures: Stock Market Reels As Nvidia, Super Micro Crack. Tesla, Microsoft, Meta Due Investor's Business Daily ...
In Article Trend: Neutral
April 19, 2024 (18:39) / "Investors Business Daily" (by Investor's Business Daily)
Even Medical Products Stocks Don't All Look Healthy In This Sick Market
Investors often turn to defensive types of stocks including medical companies in times of market turmoil, but even those can produce mixed results. Take IBD 50 medical products stocks such as Dexcom ( DXCM ) , which has wavered in a buy zone but ultimately slipped below its entry point.
In Article Trend: Neutral
April 19, 2024 (14:56) / "Investors Business Daily" (by KEN SHREVE)
Magnificent Meta Stock Holds Strong Amid Expectations For Bullish Quarter
Leading growth stocks are under pressure along with the broad market, but not Meta Platforms ( META ) , which will report earnings in the coming week.
In Article Trend: Somewhat-Bullish
April 19, 2024 (12:30) / "Investors Business Daily" (by Investor's Business Daily)
Dexcom In Buy Zone After Launch Of Prescription-Free Diabetes Monitor; Earnings Due Next Week
Dexcom Stock Is In Buy Zone Ahead Of Earnings Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 19, 2024 (11:00) / "Zacks Commentary" (by Benjamin Rains)
3 Innovative Stocks to Buy Before Earnings Amid the Market Pullback
Long-term investors are often well-served to buy stocks amid bouts of weakness.
In Article Trend: Neutral
April 18, 2024 (14:33) / "Investors Business Daily" (by ALLISON GATLIN)
Could Eli Lilly's Sleep Apnea News Actually Help This CPAP Maker?
ResMed Stock Reverses Higher As Weight-Loss Drugs Seen Bolstering Its Devices Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 18, 2024 (12:26) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Retain DexCom ( DXCM ) Stock in Your Portfolio for Now
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
In Article Trend: Somewhat-Bullish
April 18, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Establishment Labs Hldgs Shows Rising Price Performance With Jump To 84 RS Rating
On Thursday, Establishment Labs Hldgs ( ESTA ) received an upgrade to its Relative Strength ( RS ) Rating, from 80 to 84. X IBD's proprietary RS Rating identifies technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our ...
In Article Trend: Somewhat-Bullish
April 18, 2024 (07:00) / "Investors Business Daily" (by Investor's Business Daily)
Stocks Flashing Renewed Technical Strength: Inspire Medical Systems
Inspire Medical Systems ( INSP ) had its Relative Strength ( RS ) Rating upgraded from 67 to 84 Thursday. X This unique rating tracks technical performance by using a 1 ( worst ) to 99 ( best ) score that indicates how a stock's price performance over the trailing 52 weeks matches up against ...
In Article Trend: Bullish
April 17, 2024 (19:00) / "Benzinga" (by Benzinga Insights)
$1000 Invested In DexCom 5 Years Ago Would Be Worth This Much Today - DexCom ( NASDAQ:DXCM )
DexCom DXCM has outperformed the market over the past 5 years by 23.93% on an annualized basis producing an average annual return of 35.38%. Currently, DexCom has a market capitalization of $51.74 billion.
In Article Trend: Somewhat-Bullish
April 17, 2024 (11:52) / "Investors Business Daily" (by Investor's Business Daily)
Abbott Labs Jumps, Retreats On Q1 Beat, Shy Guidance
Abbott stock see-sawed early Wednesday after the giant health care company reported adjusted income of 98 cents a share on $10 billion in first-quarter sales. The Street projected earnings of 95 cents a share and $9.88 billion in sales, according to FactSet.
In Article Trend: Somewhat-Bullish
April 17, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Boston Scientific Joins Elite List Of Stocks With 95-Plus Composite Rating
On Wednesday, Boston Scientific ( BSX ) got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. X The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength.
In Article Trend: Somewhat-Bullish
April 16, 2024 (12:57) / "Investors Business Daily" (by ALLISON GATLIN)
Health Care Bellwether J&J Misses Sales Views, But Profit Beats
Johnson & Johnson Stock Dips On Light Sales, But Earnings Beat Forecasts Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 16, 2024 (08:34) / "Zacks Commentary" (by Zacks Investment Research)
Zacks Industry Outlook Highlights Edwards Lifesciences, DexCom and STERIS
Edwards Lifesciences, DexCom and STERIS have been highlighted in this Industry Outlook article.
In Article Trend: Neutral
April 15, 2024 (22:15) / "Zacks Commentary" (by Zacks Equity Research)
DexCom ( DXCM ) Stock Moves -1.16%: What You Should Know
In the latest trading session, DexCom (DXCM) closed at $134.56, marking a -1.16% move from the previous day.
In Article Trend: Somewhat-Bullish
April 15, 2024 (15:16) / "Zacks Commentary" (by Urmimala Biswas)
3 Medical Instruments Stocks to Buy Amid Improving Industry Trends
The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth. EW, DXCM and STE appear well-poised to brave the challenges.
In Article Trend: Neutral
April 15, 2024 (14:54) / "Zacks Commentary" (by Zacks Equity Research)
DexCom ( DXCM ) , MD Revolution Unite to Boost Diabetes Management
DexCom (DXCM) and MD Revolution collaborate to integrate Dexcom's continuous glucose monitoring systems with MD Revolution's remote care management platform to boost remote diabetes management.
In Article Trend: Bullish
April 15, 2024 (14:06) / "Investors Business Daily" (by ALLISON GATLIN)
Biotech Stock Hits 2024 Low Side Effects In Rabbits Torpedo Schizophrenia Drug
Neumora Therapeutics ( NMRA ) said Monday the Food and Drug Administration put its schizophrenia drug on hold after rabbits who received it experienced convulsions. In response, the biotech stock plunged.
In Article Trend: Neutral
April 12, 2024 (13:55) / "Investors Business Daily" (by ALLISON GATLIN)
Zoetis Stock Dives On Report Arthritis Shots Sickened Dogs, Cats
Zoetis ( ZTS ) stock crumbled Friday after a Wall Street Journal report suggested the company's arthritis shots, Librela and Solensia, could have sickened dogs and cats. The shots, which gained Food and Drug Administration approval in 2022 and 2023, respectively, are the first antibody drugs ...
In Article Trend: Neutral
April 11, 2024 (20:32) / "Benzinga" (by Benzinga Insights)
This Is What Whales Are Betting On DexCom - DexCom ( NASDAQ:DXCM )
Deep-pocketed investors have adopted a bullish approach towards DexCom DXCM, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
In Article Trend: Somewhat-Bullish
April 11, 2024 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
Is DexCom ( DXCM ) Outperforming Other Medical Stocks This Year?
Here is how DexCom (DXCM) and Anika Therapeutics (ANIK) have performed compared to their sector so far this year.
In Article Trend: Somewhat-Bullish
April 11, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Stocks Showing Market Leadership: TransMedics Group Earns 92 RS Rating
On Thursday, TransMedics Group ( TMDX ) hit an important performance benchmark, seeing its Relative Strength ( RS ) Rating jump into the 90-plus percentile with an improvement to 92, up from 87 the day before.
In Article Trend: Bullish
April 11, 2024 (07:00) / "Investors Business Daily" (by Investor's Business Daily)
Inspire Medical Systems Sees IBD RS Rating Climb To 76
Inspire Medical Systems ( INSP ) saw a positive improvement to its Relative Strength ( RS ) Rating on Thursday, rising from 65 to 76. X This unique rating measures technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our ...
In Article Trend: Bullish
April 11, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
IBD Rating Upgrades: LivaNova Flashes Improved Technical Strength
LivaNova ( LIVN ) had its Relative Strength ( RS ) Rating upgraded from 67 to 73 Thursday - a welcome improvement, but still shy of the 80 or better score you look for.
In Article Trend: Bullish
April 9, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should First Trust Growth Strength ETF ( FTGS ) Be on Your Investing Radar?
Style Box ETF report for ...
In Article Trend: Somewhat-Bullish
April 8, 2024 (22:00) / "Zacks Commentary" (by Zacks Equity Research)
Why the Market Dipped But DexCom ( DXCM ) Gained Today
In the most recent trading session, DexCom (DXCM) closed at $139.94, indicating a +0.73% shift from the previous trading day.
In Article Trend: Somewhat-Bullish
April 8, 2024 (18:44) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
DexCom Stock Sees IBD Stock Market Rating Sweetens Ups; Earns 83 RS Rating
DexCom Stock Sees IBD Stock Market Rating Sweetens Ups. Earns 83 RS Rating Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 8, 2024 (15:53) / "Benzinga" (by Globe Newswire)
Precision Neuroscience Names Verily Co-Founder Brian Otis as Chief Technology Officer
NEW YORK, April 08, 2024 ( GLOBE NEWSWIRE ) -- Precision Neuroscience Corporation ( Precision ) today announced that Dr. Brian Otis has joined the company as Chief Technology Officer. An expert in chip design for low-power electronics, Dr. Otis is one of the leading technologists working ...
In Article Trend: Somewhat-Bullish
April 8, 2024 (12:30) / "Motley Fool" (by Prosper Junior Bakiny)
2 Growth Stocks to Buy Hand Over Fist in April
These healthcare companies' target markets substantially overlap.
In Article Trend: Somewhat-Bullish
April 8, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Stocks Showing Improving Market Leadership: DexCom Earns 84 RS Rating
The Relative Strength ( RS ) Rating for DexCom ( DXCM ) entered a new percentile Monday, with a rise from 80 to 84. X IBD's proprietary RS Rating tracks technical performance by showing how a stock's price action over the last 52 weeks compares to that of other stocks on the major indexes.
In Article Trend: Somewhat-Bullish
April 8, 2024 (07:00) / "Investors Business Daily" (by Investor's Business Daily)
Stocks With Rising Relative Price Strength: TransMedics Group
TransMedics Group ( TMDX ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Monday, rising from 64 to 83. X IBD's unique RS Rating tracks market leadership by showing how a stock's price action over the last 52 weeks measures up against that of other stocks on the major ...
In Article Trend: Bullish
April 8, 2024 (07:00) / "Investors Business Daily" (by Investor's Business Daily)
Stocks To Watch: Staar Surgical Sees RS Rating Rise To 87
On Monday, Staar Surgical ( STAA ) hit an important technical milestone, seeing its Relative Strength ( RS ) Rating jump into the 80-plus percentile with an improvement to 87, up from 80 the day before.
In Article Trend: Somewhat-Bullish
April 4, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
DexCom, Inc. ( DXCM ) is Attracting Investor Attention: Here is What You Should Know
DexCom (DXCM) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
In Article Trend: Somewhat-Bullish
April 3, 2024 (06:12) / "Stocknews.com" (by Defense World Staff)
DexCom ( NASDAQ:DXCM ) Upgraded to Buy at StockNews.com
DexCom ( NASDAQ:DXCM - Get Free Report ) was upgraded by research analysts at StockNews.com from a "hold" rating to a "buy" rating in a report issued on Wednesday.
In Article Trend: Somewhat-Bullish
April 2, 2024 (22:00) / "Zacks Commentary" (by Zacks Equity Research)
DexCom ( DXCM ) Falls More Steeply Than Broader Market: What Investors Need to Know
In the closing of the recent trading day, DexCom (DXCM) stood at $136.65, denoting a -0.94% change from the preceding trading day.
In Article Trend: Somewhat-Bullish
April 2, 2024 (16:58) / "Zacks Commentary" (by Zacks Equity Research)
Tenet ( THC ) Divests Six Hospitals, Sustains Divestiture Spree
Tenet Healthcare (THC) completes the sale of six California hospitals, four to UCI Health and two to Adventist Health, to refine the portfolio and reduce debt burden.
In Article Trend: Somewhat-Bullish
April 1, 2024 (14:41) / "Zacks Commentary" (by Zacks Equity Research)
Tandem Diabetes ( TNDM ) Gains From Innovation Amid Macro Issues
Tandem Diabetes (TNDM) seeks to grow its business through the acquisition of products or technologies and investments in businesses.
In Article Trend: Somewhat-Bullish
April 1, 2024 (12:11) / "Benzinga" (by Avi Kapoor)
Micron, Dropbox And 2 Other Stocks Insiders Are Selling - Dropbox ( NASDAQ:DBX ) , DexCom ( NASDAQ:DXCM )
The Nasdaq 100 closed lower by around 0.1% on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.
In Article Trend: Somewhat-Bullish
March 30, 2024 (11:45) / "Motley Fool" (by Motley Fool Staff)
Market Cap Game Show: Andy Cross vs. Bill Mann
Join the "Rule Breaker Investing" fun.
In Article Trend: Somewhat-Bullish
March 29, 2024 (16:00) / "Zacks Commentary" (by Zacks Equity Research)
DexCom ( DXCM ) Upgraded to Buy: What Does It Mean for the Stock?
DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
In Article Trend: Somewhat-Bullish
March 28, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Tandem Diabetes Care Shows Rising Price Performance With Jump To 85 RS Rating
Tandem Diabetes Care ( TNDM ) saw a positive improvement to its Relative Strength ( RS ) Rating on Thursday, with an increase from 78 to 85. X This exclusive rating from Investor's Business Daily tracks price action with a 1 ( worst ) to 99 ( best ) score.
In Article Trend: Bullish
March 27, 2024 (19:03) / "Investors Business Daily" (by SCOTT LEHTONEN)
Diabetes Play Tops Buy Point In Rally To New Highs
Dexcom Stock Tops Buy Point After FDA Clears Device Likely To Be Used For Weight Loss Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 27, 2024 (14:56) / "Zacks Commentary" (by Zacks Equity Research)
DexCom ( DXCM ) Hits 52-Week High: What's Driving the Stock?
Investors are optimistic about DexCom's (DXCM) strong product portfolio.
In Article Trend: Somewhat-Bullish
March 27, 2024 (06:58) / "Stocknews.com" (by Defense World Staff)
StockNews.com Lowers DexCom ( NASDAQ:DXCM ) to Hold
StockNews.com downgraded shares of DexCom ( NASDAQ:DXCM - Free Report ) from a buy rating to a hold rating in a research note published on Tuesday. DXCM has been the topic of a number of other research reports. Royal Bank of Canada initiated coverage on shares of DexCom in a research report on ...
In Article Trend: Somewhat-Bullish
March 26, 2024 (22:00) / "Zacks Commentary" (by Zacks Equity Research)
DexCom ( DXCM ) Stock Moves -0.12%: What You Should Know
In the latest trading session, DexCom (DXCM) closed at $139.93, marking a -0.12% move from the previous day.
In Article Trend: Somewhat-Bullish
March 26, 2024 (17:56) / "Investors Business Daily" (by JAMES DETAR)
Dexcom Stock Shows Market Leadership, Gets Rating Upgrade. Prognosis Good.
Dexcom Stock A Leader. Prognosis Good Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 26, 2024 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
Has DexCom ( DXCM ) Outpaced Other Medical Stocks This Year?
Here is how DexCom (DXCM) and Anika Therapeutics (ANIK) have performed compared to their sector so far this year.
In Article Trend: Somewhat-Bullish
March 26, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
DexCom Shows Market Leadership With Jump To 85 RS Rating
On Tuesday, DexCom ( DXCM ) got a positive adjustment to its Relative Strength ( RS ) Rating, from 77 to 85. X This exclusive rating from Investor's Business Daily tracks share price movement with a 1 ( worst ) to 99 ( best ) score.
In Article Trend: Bullish
March 25, 2024 (20:21) / "Investors Business Daily" (by ED CARSON)
Hot AI Stocks Super Micro, Micron Lead S&P 500
S&P 500: AI Stocks Super Micro, Micron Lead Index Monday Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 25, 2024 (18:30) / "Benzinga" (by Benzinga Insights)
Here's How Much $1000 Invested In DexCom 15 Years Ago Would Be Worth Today - DexCom ( NASDAQ:DXCM )
DexCom DXCM has outperformed the market over the past 15 years by 25.38% on an annualized basis producing an average annual return of 38.72%. Currently, DexCom has a market capitalization of $51.42 billion.
In Article Trend: Somewhat-Bullish
March 25, 2024 (14:57) / "Investors Business Daily" (by Investor's Business Daily)
Dow Jones Dips Even As Boeing Rallies On CEO News; This Bill Ackman Stock On 43% Run Eyes Entry
Dow Jones Dips Even As Boeing Rallies On CEO News. This Bill Ackman Stock On 43% Run Eyes Entry Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 25, 2024 (12:10) / "Investors Business Daily" (by Investor's Business Daily)
Futures Drop As These 2 Chip Giants Tumble
Stock Market Today: Dow Jones Drop As Intel, AMD Sell Off. Tesla Stock Slides On Downgrade Investor's Business Daily ...
In Article Trend: Neutral
March 25, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Stocks Generating Improved Relative Strength: LivaNova
In a welcome move, LivaNova ( LIVN ) saw its Relative Strength Rating improve from 66 to 71 on Monday. X IBD's proprietary RS Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
In Article Trend: Somewhat-Bullish
March 23, 2024 (12:00) / "Investors Business Daily" (by KIT NORTON)
S&P 500 Giants Lead 5 Stocks Near Buy Points
S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 22, 2024 (21:23) / "Investors Business Daily" (by ALAN R. ELLIOTT)
Out Like A Lamb? Rally Leans Toward A Fifth Straight Month
Out Like A Lamb? Stock Market Rally Leans Toward A Fifth Straight Month Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 22, 2024 (17:02) / "Zacks Commentary" (by Zacks Equity Research)
Compelling Reasons to Hold on to UnitedHealth Group ( UNH ) Stock
UnitedHealth Group (UNH) remains well-poised for growth on the back of improved premiums, acquisitions and partnerships, an in-demand telehealth services suite and solid cash-generating abilities.
In Article Trend: Bullish
March 22, 2024 (16:24) / "Zacks Commentary" (by Zacks Equity Research)
Tandem Diabetes ( TNDM ) Gains From Innovation Amid Competition
Tandem Diabetes (TNDM), in 2024, intends to advance its AID algorithm and expand its indications to include people living with Type 2 diabetes.
In Article Trend: Somewhat-Bullish
March 22, 2024 (12:16) / "Investors Business Daily" (by Investor's Business Daily)
Futures Mixed Ahead Of Powell Speech
Stock Market Today: Dow Jones Slips Ahead Of Powell Speech. Tesla Slides On Production Cut Investor's Business Daily ...
In Article Trend: Neutral
March 21, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
DexCom, Inc. ( DXCM ) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching DexCom (DXCM) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
In Article Trend: Somewhat-Bullish
March 21, 2024 (12:19) / "Investors Business Daily" (by Investor's Business Daily)
Futures Rise, As Micron Soars On Earnings
Stock Market Today: Dow Jones Rises Ahead Of Jobless Claims. Reddit IPO To Debut Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 21, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
IBD Rating Upgrades: Tandem Diabetes Care Shows Improved Technical Strength
Tandem Diabetes Care ( TNDM ) had its Relative Strength ( RS ) Rating upgraded from 62 to 73 Thursday - a welcome improvement, but still short of the 80 or better score you prefer to see. X This exclusive rating from Investor's Business Daily measures price performance with a 1 ( worst ) to ...
In Article Trend: Bullish
March 20, 2024 (18:45) / "Benzinga" (by Benzinga Insights)
DexCom's Options: A Look at What the Big Money is Thinking - DexCom ( NASDAQ:DXCM )
Benzinga's options scanner has just identified more than 8 option transactions on DexCom DXCM, with a cumulative value of $548,553. Concurrently, our algorithms picked up 5 puts, worth a total of 372,044.
In Article Trend: Somewhat-Bullish
March 20, 2024 (12:12) / "Investors Business Daily" (by Investor's Business Daily)
Futures Mixed Ahead Of Fed Decision, Powell
Stock Market Today: Dow Jones Falls Ahead Of Fed, Powell. Super Micro Slides On Offering Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 19, 2024 (22:00) / "Zacks Commentary" (by Zacks Equity Research)
DexCom ( DXCM ) Stock Sinks As Market Gains: Here's Why
DexCom (DXCM) closed at $134.17 in the latest trading session, marking a -0.41% move from the prior day.
In Article Trend: Somewhat-Bullish
March 19, 2024 (20:46) / "Investors Business Daily" (by Investor's Business Daily)
Nvidia Leads Market Rebound, But Fed Looms Large
Dow Jones futures were little changed after hours, along with S&P 500 futures and Nasdaq futures. The Federal Reserve will conclude its two-day meeting on Wednesday afternoon, with the Fed's rate-cut outlook in focus. The stock market rally had modest gains Tuesday, battling back from initial ...
In Article Trend: Somewhat-Bullish
March 19, 2024 (18:24) / "Investors Business Daily" (by JULIE MAK)
Edwards Lifesciences Stock Earns Relative Strength Rating Upgrade; Hits Key Benchmark
Edwards Lifesciences Stock Earns Relative Strength Rating Upgrade. Hits Key Benchmark Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 19, 2024 (12:15) / "Investors Business Daily" (by Investor's Business Daily)
Futures Drop Ahead Of Fed Meeting
Stock Market Today: Dow Jones Falls Ahead Of Fed Meeting. AI Stock Super Micro Plunges Investor's Business Daily ...
In Article Trend: Neutral
March 19, 2024 (12:14) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Tandem Diabetes ( TNDM ) Now
Product innovations and strategic progress bode well for Tandem Diabetes (TNDM).
In Article Trend: Somewhat-Bullish
March 19, 2024 (11:12) / "Associated Press" (by ERIC OLSON)
Creighton's Isaac Traudt wears glucose monitor to stay in game. His diabetes was diagnosed at age 4
OMAHA, Neb. ( AP ) - When Creighton basketball player Isaac Traudt's teammates take a break at practice, they might grab a drink of water, chat it up or go over assignments. Traudt does that, too, but not before he checks a device attached to his body that tells him his blood glucose level.
In Article Trend: Neutral
March 19, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Stocks Showing Market Leadership: Establishment Labs Hldgs Earns 92 RS Rating
Establishment Labs Hldgs ( ESTA ) had its Relative Strength ( RS ) Rating upgraded from 87 to 92 Tuesday. X This exclusive rating from Investor's Business Daily tracks market leadership with a 1 ( worst ) to 99 ( best ) score.
In Article Trend: Somewhat-Bullish
March 19, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Edwards Lifesciences Earns Relative Strength Rating Upgrade; Hits Key Benchmark
Edwards Lifesciences Earns Relative Strength Rating Upgrade. Hits Key Benchmark Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 19, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Repligen Getting Closer To Key Technical Measure
Repligen ( RGEN ) saw a positive improvement to its Relative Strength ( RS ) Rating on Tuesday, rising from 69 to 76. X This exclusive rating from Investor's Business Daily tracks price performance with a 1 ( worst ) to 99 ( best ) score.
In Article Trend: Bullish
March 18, 2024 (18:47) / "Investors Business Daily" (by Investor's Business Daily)
DexCom Stock Trying To Close In On Key Technical Benchmark
In a welcome move, DexCom ( DXCM ) stock saw its Relative Strength Rating improve from 68 to 73 on Monday. This unique rating measures technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
In Article Trend: Somewhat-Bullish
March 18, 2024 (13:29) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Retain DexCom ( DXCM ) Stock in Your Portfolio for Now
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
In Article Trend: Somewhat-Bullish
March 18, 2024 (12:21) / "Investors Business Daily" (by Investor's Business Daily)
Tech Futures Jump As Nvidia, Tesla Rally
Stock Market Today: Dow Jones Rises As Nvidia AI Event Looms. Tesla Jumps On Price Hikes Investor's Business Daily ...
In Article Trend: Neutral
March 18, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
DexCom Trying To Close In On Key Technical Benchmark
In a welcome move, DexCom ( DXCM ) saw its Relative Strength Rating improve from 68 to 73 on Monday. X This unique rating measures technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
In Article Trend: Bullish
March 16, 2024 (06:48) / "Stocknews.com" (by Defense World Staff)
DexCom ( NASDAQ:DXCM ) Upgraded by StockNews.com to Buy
DexCom ( NASDAQ:DXCM - Get Free Report ) was upgraded by investment analysts at StockNews.com from a "hold" rating to a "buy" rating in a research note issued to investors on Saturday. DXCM has been the topic of a number of other reports.
In Article Trend: Somewhat-Bullish
March 15, 2024 (16:46) / "Zacks Commentary" (by Zacks Equity Research)
Encompass Health ( EHC ) Up 42% in a Year: What Lies Ahead?
Encompass Health (EHC) remains well-poised for growth on the back of sustained top-line growth, an expanding healthcare facility portfolio and robust cash-generating abilities.
In Article Trend: Somewhat-Bullish
March 15, 2024 (12:21) / "Investors Business Daily" (by Investor's Business Daily)
Futures Rise, But This Software Giant Plunges
Stock Market Today: Dow Jones Rises As Adobe Dives. Cathie Wood Loads Up On Tesla Stock Investor's Business Daily ...
In Article Trend: Neutral
March 14, 2024 (20:51) / "Investors Business Daily" (by ALLISON GATLIN)
Robotic Surgery Giant Wins FDA OK For Next-Gen System; Shares Pop
Intuitive Surgical Stock Pops After Winning FDA Clearance For Next-Gen Robotic Surgery Investor's Business Daily ...
In Article Trend: Bullish
March 14, 2024 (20:30) / "Benzinga" (by Benzinga Insights)
Here's How Much You Would Have Made Owning DexCom Stock In The Last 15 Years - DexCom ( NASDAQ:DXCM )
DexCom DXCM has outperformed the market over the past 15 years by 24.4% on an annualized basis producing an average annual return of 37.94%. Currently, DexCom has a market capitalization of $49.99 billion.
In Article Trend: Somewhat-Bullish
March 14, 2024 (16:23) / "Investors Business Daily" (by Investor's Business Daily)
This Biotech, Up 62%, Could Launch A First In Liver Disease; Why Shares Dipped
Madrigal Stock Slumps Ahead Of Potential Approval For First-Ever MASH Treatment Investor's Business Daily ...
In Article Trend: Neutral
March 14, 2024 (15:15) / "Investors Business Daily" (by VIDYA RAMAKRISHNAN)
Stocks Retreat; Nvidia, Super Micro Fall After Analysts Raise Price Targets, But Cathie Wood's Holding Soars
Stock Market Today: Dow Jones Slips As Nvidia and Super Micro Get Price Upgrades Investor's Business Daily ...
In Article Trend: Neutral
March 14, 2024 (13:48) / "Zacks Commentary" (by Nalak Das)
Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024
We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.
In Article Trend: Bullish
March 14, 2024 (13:30) / "Zacks Commentary" (by Zacks Equity Research)
Is It Worth Investing in DexCom ( DXCM ) Based on Wall Street's Bullish Views?
According to the average brokerage recommendation (ABR), one should invest in DexCom (DXCM). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
In Article Trend: Somewhat-Bullish
March 14, 2024 (13:02) / "Zacks Commentary" (by Zacks Equity Research)
Zacks Investment Ideas feature highlights: Tenet Healthcare and HCA Healthcare
Tenet Healthcare and HCA Healthcare are part of the Zacks Investment Ideas article.
In Article Trend: Somewhat-Bullish
March 14, 2024 (12:17) / "Investors Business Daily" (by Investor's Business Daily)
Futures Rise Ahead Of Key Inflation Data
Stock Market Today: Dow Jones Rises Ahead Of Key Inflation Data. Nvidia, Tesla Extend Losses Investor's Business Daily ...
In Article Trend: Neutral
March 14, 2024 (12:11) / "Investors Business Daily" (by SCOTT LEHTONEN)
Futures Rise Ahead Of Key Inflation Data
Stock Market Today: Dow Jones Rises Ahead Of Key Inflation Data. Nvidia, Tesla Extend Losses Investor's Business Daily ...
In Article Trend: Neutral
March 13, 2024 (20:49) / "Investors Business Daily" (by ED CARSON)
Market Rally Resilient, But This Gauge Should Worry You
Dow Jones futures edged higher after hours, along with S&P 500 futures and Nasdaq futures. Software makers UiPath ( PATH ) and SentinelOne ( S ) reported Wednesday night, with Lennar ( LEN ) on tap. The stock market rally had a constructive Wednesday.
In Article Trend: Neutral
March 13, 2024 (16:38) / "Zacks Commentary" (by Bryan Hayes)
Medical Devices ETF Hits 52-Week High: Stocks to Watch
Historically viewed as a defensive area, health care also boasts many growth aspects and benefits from advances in technology.
In Article Trend: Somewhat-Bullish
March 13, 2024 (16:04) / "Investors Business Daily" (by ALLISON GATLIN)
IBD Stock Of The Day Lingers In Buy Zone As Diabetes Play Eyes Obesity
Dexcom ( DXCM ) is Wednesday's IBD Stock Of The Day. Dexcom stock is lingering in a buy zone, bolstered by U.S. clearance of a new body-worn glucose monitor. The company developed Stelo, its newest continuous glucose monitor, for the roughly 25 million people in the U.S. with type 2 diabetes ...
In Article Trend: Neutral
March 13, 2024 (11:56) / "Zacks Commentary" (by Zacks Equity Research)
Roche ( RHHBY ) Launches AI-Based Predictive CGM Accu-Chek
Roche (RHHBY) is likely to enter the growing diabetes market with its AI-enabled predictive glucose monitoring system that may revolutionize diabetes management.
In Article Trend: Somewhat-Bullish
March 13, 2024 (11:25) / "Investors Business Daily" (by ED CARSON)
Futures: Five Stocks Flash Buy Signals; Tesla Gets Sell Rating
Futures: Five Stocks Flash Buy Signals. Tesla Gets Sell Rating Investor's Business Daily ...
In Article Trend: Neutral
March 12, 2024 (20:50) / "Investors Business Daily" (by Investor's Business Daily)
Big Techs Rebound; Five Stocks Flash Buy Signals
Dow Jones Futures: Oracle, Nvidia Lead S&P 500 To Record Close. 5 Stocks Flash Buy Signals Investor's Business Daily ...
In Article Trend: Neutral
March 12, 2024 (15:54) / "Benzinga" (by Priya Nigam)
DexCom Is 'Expanding Rapidly' With Multi-Year Runway Ahead, Bullish Analyst Says - DexCom ( NASDAQ:DXCM )
DexCom Inc's DXCM Stelo Glucose Biosensor System has been approved by the Food and Drug Administration ( FDA ) as the first over-the-counter ( OTC ) continuous glucose monitor ( CGM ) .
In Article Trend: Somewhat-Bullish
March 11, 2024 (22:00) / "Zacks Commentary" (by Zacks Equity Research)
DexCom ( DXCM ) Sees a More Significant Dip Than Broader Market: Some Facts to Know
The latest trading day saw DexCom (DXCM) settling at $133.04, representing a -1.63% change from its previous close.
In Article Trend: Somewhat-Bullish
March 11, 2024 (18:03) / "Investors Business Daily" (by JULIE MAK)
Tandem Diabetes Care Stock Belongs On Your Watchlist As RS Rating Jump Higher
On Monday, Tandem Diabetes Care ( TNDM ) stock received an upgrade to its Relative Strength ( RS ) Rating, from 68 to 78. This unique rating tracks technical performance by using a 1 ( worst ) to 99 ( best ) score that identifies how a stock's price action over the trailing 52 weeks stacks up ...
In Article Trend: Somewhat-Bullish
March 11, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Stocks With Rising Relative Strength: Baxter International
Baxter International ( BAX ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Monday, rising from 70 to 73. X This proprietary rating tracks technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in ...
In Article Trend: Bullish
March 11, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Tandem Diabetes Care Trying To Close In On Key Technical Benchmark
On Monday, Tandem Diabetes Care ( TNDM ) received an upgrade to its Relative Strength ( RS ) Rating, from 68 to 78. X This unique rating tracks technical performance by using a 1 ( worst ) to 99 ( best ) score that identifies how a stock's price action over the trailing 52 weeks stacks up ...
In Article Trend: Somewhat-Bullish
March 10, 2024 (08:03) / "Stocknews.com" (by ABMN Staff)
DexCom ( NASDAQ:DXCM ) Stock Rating Lowered by StockNews.com
DexCom ( NASDAQ:DXCM ) Stock Rating Lowered by ...
In Article Trend: Somewhat-Bullish
March 10, 2024 (08:02) / "Stocknews.com" (by Defense World Staff)
DexCom ( NASDAQ:DXCM ) Stock Rating Lowered by StockNews.com
DexCom ( NASDAQ:DXCM - Get Free Report ) was downgraded by equities researchers at StockNews.com from a "buy" rating to a "hold" rating in a research report issued on Friday.
In Article Trend: Somewhat-Bullish
March 9, 2024 (15:00) / "CNBC" (by Ashley Capoot)
Signos uses a glucose monitor patch and AI to help you eat healthier. Here's what it's like
Signos uses continuous glucose monitors, or CGMs, and an artificial intelligence-powered app to help people better understand their metabolisms.
In Article Trend: Neutral
March 9, 2024 (13:00) / "Investors Business Daily" (by APARNA NARAYANAN)
AI Play ServiceNow Setting Up As Three Stocks Flash Buy Signals
ServiceNow ( NOW ) headlines stocks near buy points, backing off an aggressive entry. Meanwhile, XP ( XP ) , Block ( SQ ) and Dexcom ( DXCM ) are above buy points or early entries. The relative strength lines of most of these stocks are trending higher or improving, though XP is a partial ...
In Article Trend: Somewhat-Bullish
March 8, 2024 (22:33) / "Investors Business Daily" (by Investor's Business Daily)
Oracle, Dick's Sport Goods, Adobe And Lennar: Investing Action Pla
All three major stock market benchmarks ended lower for the week, holding just off record highs and neatly above short-term support. Oracle ( ORCL ) , Lennar ( LEN ) , Dick's Sporting Goods ( DKS ) and Adobe ( ADBE ) headline the coming week's earnings calendar.
In Article Trend: Somewhat-Bullish
March 8, 2024 (19:31) / "Investors Business Daily" (by Investor's Business Daily)
Novo's Weight-Loss Blockbuster Wins Another Approval
Novo Nordisk Stock Slumps Despite Winning Approval For Weight-Loss Drug For Heart Benefit Investor's Business Daily ...
In Article Trend: Neutral
March 8, 2024 (15:12) / "Investors Business Daily" (by Investor's Business Daily)
Amylyx Wipes 84% Off Its Value After Its ALS Drug Fails
Amylyx Stock Crashes After ALS Treatment Fails In Its Pivotal Study Investor's Business Daily ...
In Article Trend: Neutral
March 8, 2024 (15:08) / "Investors Business Daily" (by ALLISON GATLIN)
Biogen Surges On A Setback For Lilly's Rival Alzheimer's Drug
Biogen Stock Surges After FDA Delays Its Decision On Eli Lilly's Alzheimer's Treatment Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 8, 2024 (14:15) / "Motley Fool" (by David Jagielski)
2 Medical Device Stocks to Buy Hand Over Fist in March
Don't let their modest gains over the past year mislead you. these stocks can make for great long-term investments.
In Article Trend: Bullish
March 8, 2024 (13:30) / "Zacks Commentary" (by Zacks Equity Research)
Community Health ( CYH ) , Cost Plus Drugs Unite to Lower Drug Cost
Community Health (CYH) collaborates with Cost Plus Drug to reduce drug costs and shortages.
In Article Trend: Somewhat-Bullish
March 8, 2024 (12:57) / "Zacks Commentary" (by Zacks Equity Research)
DexCom's ( DXCM ) Direct-to-Watch Feature to Boost Its G7 System
DexCom (DXCM) announces its direct-to-Apple-Watch feature for the G7 CGM system, which is likely to help people in better management of diabetes monitoring.
In Article Trend: Somewhat-Bullish
March 8, 2024 (10:41) / "Zacks Commentary" (by Zacks Equity Research)
DexCom ( DXCM ) Soars 10% This Week: What's Fueling the Gain?
A recent approval for DexCom's (DXCM) new CGM device boosts the prospects of the company by broadening the targeted market. Shares gain as investors see strong potential for growth going forward.
In Article Trend: Somewhat-Bullish
March 8, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Stocks To Watch: Edwards Lifesciences Sees RS Rating Jump To 87
Edwards Lifesciences ( EW ) saw a positive improvement to its Relative Strength ( RS ) Rating on Friday, with an upgrade from 80 to 87. X This exclusive rating from Investor's Business Daily tracks market leadership with a 1 ( worst ) to 99 ( best ) score.
In Article Trend: Bullish
March 8, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Align Technology Getting Closer To Key Technical Benchmark
In a welcome move, Align Technology ( ALGN ) saw its Relative Strength Rating improve from 68 to 73 on Friday. X IBD's unique RS Rating measures technical performance by using a 1 ( worst ) to 99 ( best ) score that shows how a stock's price action over the last 52 weeks matched up against all ...
In Article Trend: Somewhat-Bullish
March 7, 2024 (14:40) / "Zacks Commentary" (by Zacks Equity Research)
Are Medical Stocks Lagging DexCom ( DXCM ) This Year?
Here is how DexCom (DXCM) and Ambrx Biopharma Inc. (AMAM) have performed compared to their sector so far this year.
In Article Trend: Somewhat-Bullish
March 7, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)
Investors Heavily Search DexCom, Inc. ( DXCM ) : Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to DexCom (DXCM). This makes it worthwhile to examine what the stock has in store.
In Article Trend: Somewhat-Bullish
March 7, 2024 (13:51) / "Benzinga" (by Avi Kapoor)
Palantir Technologies, SL Green Realty And A Healthcare Stock On CNBC's 'Final Trades' - DexCom ( NASDAQ:DXCM ) , Palantir Technologies ( NYSE:PLTR )
On CNBC's "Halftime Report Final Trades," Jenny Harrington of Gilman Hill Asset Management named SL Green Realty Corp. SLG, which has a 6% dividend yield. On Jan. 24, SL Green Realty posted weaker-than-expected results for its fourth quarter, posting sales of $131.93 million, missing market ...
In Article Trend: Somewhat-Bullish
March 7, 2024 (08:43) / "Zacks Commentary" (by Zacks Equity Research)
DexCom ( DXCM ) Soars 9.8%: Is Further Upside Left in the Stock?
DexCom (DXCM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
In Article Trend: Somewhat-Bullish
March 6, 2024 (21:48) / "Benzinga" (by Vandana Singh)
FDA Approval For DexCom's Stelo Opens Continuous Glucose Monitoring To Masses, Analyst Expects Competitive Pricing Against Abbott's - DexCom ( NASDAQ:DXCM )
Tuesday, the FDA approved DexCom Inc's DXCM Stelo Glucose Biosensor System as the first over-the-counter ( OTC ) continuous glucose monitor ( CGM ) . The Dexcom Stelo Glucose Biosensor System is an integrated CGM ( iCGM ) intended for anyone 18 years and older who does not use insulin.
In Article Trend: Somewhat-Bullish
March 6, 2024 (21:32) / "Investors Business Daily" (by Investor's Business Daily)
Futures: AI Play Palantir Soars Into Buy Area; Watch Out For This
Dow Jones Futures: Palantir Soars Into Buy Zone, Nvidia Runs, But Beware This Investor's Business Daily ...
In Article Trend: Neutral
March 6, 2024 (15:25) / "Investors Business Daily" (by Investor's Business Daily)
Dexcom Pops As It Enters A New CGM Market: Non-Diabetics
Dexcom Stock Pops After FDA Clears Its New Continuous Glucose Monitor Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 6, 2024 (15:09) / "Zacks Commentary" (by Zacks Equity Research)
DaVita ( DVA ) Hits 52-Week High: What's Driving the Stock?
Investors are optimistic about DaVita's (DVA) strength in its kidney care.
In Article Trend: Somewhat-Bullish
March 6, 2024 (14:49) / "Zacks Commentary" (by Zacks Equity Research)
DaVita ( DVA ) Expands Operational Footprint Via New Agreement
DaVita's (DVA) latest agreement is expected to serve a wider patient pool across Latin America.
In Article Trend: Somewhat-Bullish
March 6, 2024 (14:12) / "Benzinga" (by Vandana Singh)
FDA Approves Dexcom's Stelo As First Glucose Monitoring Device Without Prescription Why Is Dexcom Stock Trading Higher Today? - DexCom ( NASDAQ:DXCM )
Tuesday, the FDA approved DexCom Inc's DXCM Stelo Glucose Biosensor System as the first over-the-counter ( OTC ) continuous glucose monitor ( CGM ) . The Dexcom Stelo Glucose Biosensor System is an integrated CGM ( iCGM ) intended for anyone 18 years and older who does not use insulin.
In Article Trend: Neutral
March 6, 2024 (13:45) / "Zacks Commentary" (by Zacks Equity Research)
DexCom's ( DXCM ) Stelo Glucose Biosensor Receives FDA Approval
DexCom's (DXCM) Stelo receives FDA clearance, which makes it the first FDA-approved glucose biosensor to be available over the counter.
In Article Trend: Somewhat-Bullish
March 6, 2024 (07:28) / "Benzinga" (by Avi Kapoor)
Campbell Soup, Box And 3 Stocks To Watch Heading Into Wednesday - Campbell Soup ( NYSE:CPB ) , Box ( NYSE:BOX )
With U.S. stock futures trading mostly higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects THOR Industries, Inc. THO to report quarterly earnings at 67 cents per share on revenue of $2.27 billion before the opening bell, ...
In Article Trend: Somewhat-Bullish
March 6, 2024 (02:21) / "CNBC" (by Ashley Capoot)
Dexcom announces its first-ever over-the-counter CGM Stelo has been cleared by the FDA
Dexcom on Tuesday announced that its new over-the-counter continuous glucose monitor called Stelo has been cleared for use by the FDA.
In Article Trend: Neutral
March 5, 2024 (22:50) / "Zacks Commentary" (by Zacks Equity Research)
DexCom ( DXCM ) Stock Moves -0.43%: What You Should Know
DexCom (DXCM) closed at $121.78 in the latest trading session, marking a -0.43% move from the prior day.
In Article Trend: Somewhat-Bullish
March 4, 2024 (23:00) / "Zacks Commentary" (by Zacks Equity Research)
DexCom ( DXCM ) Rises As Market Takes a Dip: Key Facts
In the most recent trading session, DexCom (DXCM) closed at $122.30, indicating a +0.46% shift from the previous trading day.
In Article Trend: Somewhat-Bullish
March 3, 2024 (15:15) / "Motley Fool" (by Prosper Junior Bakiny)
Adding $1,000 to These Top Growth Stocks Would Be a Brilliant Move
With patience, these stocks will provide outsized returns to investors.
In Article Trend: Somewhat-Bullish
March 3, 2024 (14:45) / "Motley Fool" (by Prosper Junior Bakiny)
Ozempic Won't Sink This Medical Device Stock's Prospects -- Quite the Opposite
There is a world of opportunities ahead for this healthcare giant.
In Article Trend: Somewhat-Bullish
March 1, 2024 (17:26) / "Zacks Commentary" (by Zacks Equity Research)
Tenet Healthcare ( THC ) to Sell Hospitals to Refine Portfolio
Tenet Healthcare (THC) enters an agreement with Adventist Health to divest two of THC's hospitals, and continue to make Conifer's revenue cycle management services available for the divested operations.
In Article Trend: Somewhat-Bullish
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website